Latest Csl News

Page 5 of 6
CSL Limited has updated its dividend announcement for the first half of FY2025, confirming a USD 1.62 per share ordinary dividend and clarifying currency payment arrangements for global shareholders.
Ada Torres
Ada Torres
12 Sept 2025
Cambium Bio has secured a strategic partnership with French pharmaceutical leader Benta SAS to commercialise its regenerative dry eye treatment, Elate Ocular, across Europe and the Middle East. This follows a second platelet-lysate licensing deal within days, underscoring growing industry confidence in Cambium’s platform.
Ada Torres
Ada Torres
5 Sept 2025
Katana Capital Limited reported a 10.63% gross investment return for the 2025 financial year, surpassing the All Ordinaries index by 1.16%. The fund’s defensive strategy and valuation discipline helped navigate a volatile market environment.
Claire Turing
Claire Turing
27 Aug 2025
CSL Limited reported solid FY25 financials with 5% revenue growth and announced a strategic transformation including a $500 million annual cost saving target and plans to spin off its vaccine business, CSL Seqirus, as a separate ASX-listed entity.
Ada Torres
Ada Torres
19 Aug 2025
CSL Limited has announced an unfranked ordinary dividend of USD 1.62 per share for the first half of 2025, with payments scheduled in multiple currencies depending on shareholder location.
Ada Torres
Ada Torres
19 Aug 2025
CSL Limited reported robust FY25 results alongside a sweeping strategic overhaul, including a major cost-saving program and plans to spin off its vaccine unit CSL Seqirus as a standalone ASX-listed company.
Ada Torres
Ada Torres
19 Aug 2025
CSL Limited posted a 14% rise in net profit for FY2025, underpinned by strong immunoglobulin sales and new product launches, while announcing plans to demerge its vaccines business, CSL Seqirus, to sharpen strategic focus.
Ada Torres
Ada Torres
19 Aug 2025
WAM Leaders Limited reported a strong $63.8 million net profit for FY2025 and declared a fully franked final dividend of 4.7 cents per share, despite its investment portfolio underperforming the benchmark index.
Claire Turing
Claire Turing
15 Aug 2025
AMCIL Limited reported a net profit of $6.7 million for FY2025, down from $7.5 million the previous year, and announced a fully franked total dividend of 6.5 cents per share, boosted by a special capital gains payout.
Claire Turing
Claire Turing
31 July 2025
Australian Foundation Investment Company Limited (AFIC) reported a $285 million net profit for FY2025, declaring a fully franked 14.5c final dividend plus a 5c special dividend tied to capital gains from portfolio adjustments.
Claire Turing
Claire Turing
28 July 2025
CSL has secured FDA approval for ANDEMBRY®, a pioneering treatment for hereditary angioedema, enabling an immediate US launch with promising clinical results. This milestone marks a significant advance in managing a rare but debilitating condition.
Ada Torres
Ada Torres
17 June 2025
INOVIQ Limited reports significant progress in its exosome-based cancer diagnostics and therapeutics, including expanded customer adoption, advanced AI screening tests, and strategic partnerships with leading research centres.
Ada Torres
Ada Torres
30 Apr 2025

Browse the archive

Full archive